1 not yet recruiting, 1 recruiting. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Tafolecimab: new trials by email Literature Review of Tafolecimab trials Research Report on Tafolecimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients Tafolecimab - Acute Myocardial Infarction (AMI) | Phase 4 | Not yet recruiting | The Affiliated Hospital of Xuzhou Medical University | 1160 | 2025-11-20 | 2025-11-21 |
| Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population Tafolecimab, Cholesterol Absorption Inhibitor, Statin - Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome | Phase 4 | Recruiting | China National Center for Cardiovascular Diseases | 3684 | 2023-11-11 | 2026-10-27 |
China National Center for Cardiovascular Diseases (1) · The Affiliated Hospital of Xuzhou Medical University (1)
China (2)
Na-Qiong Wu, Doctor (1) · Yong Huo, M.D. and Ph.D. (1) · Yong-Jian Wu, Doctor (1) · Yuan Lu, M.D. and Ph.D. (1)